Amylin’s SymlinPen To Launch In December

Firm gets mixed blessing from FDA as agency says combination of pramlintide and basal insulin is "not approvable."

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet